Hims & Hers Health
Combined average of Moat (AI Resilience), Growth, and Valuation scores.
Moat Score
DTC telehealth subscription brand with vertical pharmacy and multi-category bundle — narrow brand moat. March 2026 Novo Nordisk branded GLP-1 partnership resolved the compounding lawsuit overhang but compressed weight-loss unit economics; July 2026 FTC privacy/billing suit re-opens regulatory tail risk.
Hims's moat is brand recognition + vertical pharmacy + multi-category subscription bundling in telehealth — real but narrow, with regulatory exposure now centred on FTC consumer-protection claims and branded-GLP-1 margin mix rather than compounded-semaglutide enforcement alone:
- DTC Brand Reach in Targeted Categories: Hims has built genuine brand awareness in men's hair loss, sexual health, mental health, weight-loss, and women's hormonal health. The marketing flywheel and CAC-LTV economics in established categories remain the franchise's core; Q1 subscribers reached 2.58M (+9% YoY) even as U.S. revenue dipped on the GLP-1 mix shift.
- Vertical Pharmacy and Branded GLP-1 Access: Hims operates its own compounding pharmacies, but the March 2026 Novo Nordisk collaboration put FDA-approved Ozempic and Wegovy (injectable and oral) on the platform at Novo self-pay prices and ended Novo's patent suit. Compounded GLP-1 is now limited to clinically necessary cases — a cleaner legal channel at structurally lower margin than 2024 compounded semaglutide.
- Clinical Network and International Scale: A national provider network plus ZAVA, Livewell, and the June 2026 Eucalyptus close (Australia/Canada/Germany/Japan/UK footprint; ~850K prior customers) extend the closed-loop subscription stack. Switching costs for the patient remain low; convenience-and-pricing UX vs traditional care is the retention lever.
Moat Verdict
Hims is a brand-and-bundle moat business in a regulated industry — AI is neutral-to-positive on cost (provider productivity) but the dominant moat questions are regulatory (now FTC + compounding history) and competitive. The Novo partnership cleans up GLP-1 legality at the cost of margin; the thesis remains execution-and-category-expansion, appropriately sized as speculative growth.
56.6 resilient · 43.1 vulnerable · 80/20 = 53.9 · = 54
Open a moat to read its note.
Subscription UX and re-fill workflow drive some switching cost, but rivals can replicate the UI quickly — and FTC cancellation allegations undercut any claim that retention is earned convenience alone.
Telehealth intake-to-prescription workflows are largely commoditised software.
N/A.
DTC marketing and telehealth-clinician supply are increasingly available at scale to competitors.
Multi-category subscription bundle (hair + weight + mental health + skin) creates real ARPU expansion and retention vs single-category telehealth — Hims's primary moat lever.
Subscription health-and-outcomes data across 2.6M+ patients is real, though monetisation is constrained by HIPAA/consent — and the July 2026 FTC suit over alleged sharing with Meta/Snap puts that data advantage under active regulatory scrutiny.
No regulatory moat — telehealth and compounding rules protect nobody's position. The April 2025 GLP-1 compounding ban and the July 2026 FTC privacy/billing complaint are structural regulatory risk, charged in the growth keyRisk rather than scored here as an eroded moat. Previously weakened.
DTC subscription, not a network-effects business.
Subscription auto-fills, integrated lab workups, and chronic-care titration plans create real friction for swap-out at the patient level.
Hims is becoming the system of record for personalised chronic-care for younger demographics, but the moat is shallow vs primary care + EHR systems.
Not a source of durability for this business: no structural unit-cost gap versus rivals that the other pillars do not already capture.
Hims & Hers is a recognised direct-to-consumer telehealth brand that acquires customers with less paid spend than new entrants, but FTC scrutiny and GLP-1 compounding history dent the trust the brand relies on.
Combined average of Moat (AI Resilience), Growth, and Valuation scores.
Moat Score
DTC telehealth subscription brand with vertical pharmacy and multi-category bundle — narrow brand moat. March 2026 Novo Nordisk branded GLP-1 partnership resolved the compounding lawsuit overhang but compressed weight-loss unit economics; July 2026 FTC privacy/billing suit re-opens regulatory tail risk.
Growth Score
Q1 revenue $608M (+4% YoY) was a transition print after the branded-GLP-1 pivot; FY26 guide raised to $2.8-3.0B (+19-28%, ex-Eucalyptus) with Adj EBITDA $275-350M (10-12% margin). Q2 guide $680-700M (+25-28% YoY) is the first full quarter of branded weight-loss — results due AMC August 10, 2026 (not yet reported). 2030 targets remain ≥$6.5B revenue / $1.3B Adj EBITDA.
Valuation Score
At ~$29.30 (September 24, 2026) HIMS trades at ~2.3× FY26 sales on the ~$2.9B guide midpoint, a sharp de-rating from the ~4.5-5× / ~$50 regime in May. The base is trimmed from $42 (~3× sales) to $35 (~2.5× sales) so it sits within ~12% of the ~$31 Street mean target rather than ~34% above it. Spot sits ~33% above the $22 bear and ~16% below base; the multiple prices execution and FTC risk honestly but leaves limited cushion if H2 margins disappoint.
The DTC Telehealth Brand Moat
Hims's moat is brand recognition + vertical pharmacy + multi-category subscription bundling in telehealth — real but narrow, with regulatory exposure now centred on FTC consumer-protection claims and branded-GLP-1 margin mix rather than compounded-semaglutide enforcement alone:
- DTC Brand Reach in Targeted Categories: Hims has built genuine brand awareness in men's hair loss, sexual health, mental health, weight-loss, and women's hormonal health. The marketing flywheel and CAC-LTV economics in established categories remain the franchise's core; Q1 subscribers reached 2.58M (+9% YoY) even as U.S. revenue dipped on the GLP-1 mix shift.
- Vertical Pharmacy and Branded GLP-1 Access: Hims operates its own compounding pharmacies, but the March 2026 Novo Nordisk collaboration put FDA-approved Ozempic and Wegovy (injectable and oral) on the platform at Novo self-pay prices and ended Novo's patent suit. Compounded GLP-1 is now limited to clinically necessary cases — a cleaner legal channel at structurally lower margin than 2024 compounded semaglutide.
- Clinical Network and International Scale: A national provider network plus ZAVA, Livewell, and the June 2026 Eucalyptus close (Australia/Canada/Germany/Japan/UK footprint; ~850K prior customers) extend the closed-loop subscription stack. Switching costs for the patient remain low; convenience-and-pricing UX vs traditional care is the retention lever.
Moat Verdict
Hims is a brand-and-bundle moat business in a regulated industry — AI is neutral-to-positive on cost (provider productivity) but the dominant moat questions are regulatory (now FTC + compounding history) and competitive. The Novo partnership cleans up GLP-1 legality at the cost of margin; the thesis remains execution-and-category-expansion, appropriately sized as speculative growth.
56.6 resilient · 43.1 vulnerable · 80/20 = 53.9 · = 54
Open a moat to read its note.
Subscription UX and re-fill workflow drive some switching cost, but rivals can replicate the UI quickly — and FTC cancellation allegations undercut any claim that retention is earned convenience alone.
Telehealth intake-to-prescription workflows are largely commoditised software.
N/A.
DTC marketing and telehealth-clinician supply are increasingly available at scale to competitors.
Multi-category subscription bundle (hair + weight + mental health + skin) creates real ARPU expansion and retention vs single-category telehealth — Hims's primary moat lever.
Subscription health-and-outcomes data across 2.6M+ patients is real, though monetisation is constrained by HIPAA/consent — and the July 2026 FTC suit over alleged sharing with Meta/Snap puts that data advantage under active regulatory scrutiny.
No regulatory moat — telehealth and compounding rules protect nobody's position. The April 2025 GLP-1 compounding ban and the July 2026 FTC privacy/billing complaint are structural regulatory risk, charged in the growth keyRisk rather than scored here as an eroded moat. Previously weakened.
DTC subscription, not a network-effects business.
Subscription auto-fills, integrated lab workups, and chronic-care titration plans create real friction for swap-out at the patient level.
Hims is becoming the system of record for personalised chronic-care for younger demographics, but the moat is shallow vs primary care + EHR systems.
Not a source of durability for this business: no structural unit-cost gap versus rivals that the other pillars do not already capture.
Hims & Hers is a recognised direct-to-consumer telehealth brand that acquires customers with less paid spend than new entrants, but FTC scrutiny and GLP-1 compounding history dent the trust the brand relies on.
Growth Analysis
Growth Drivers
Key Risk
If the July 2026 FTC/state privacy-and-billing suit forces a large settlement or advertising restrictions, or if branded GLP-1 gross margin stays near the Q1 65% level without the guided H2 Adj EBITDA ramp toward ~14% margins, FY26 EBITDA misses the $275-350M band and the multiple re-rates toward 1.5× sales.
Score Derivation
86.0 base + 1.3 trajectory − 4 margin − 10 risk = 73
Base 86 (24% midpoint of 20-28%) +1.3 trajectory (international/category accelerating; weight-loss and subscribers stable through the branded pivot) −4 margin (gross margin 65% vs 73% YoY; Adj EBITDA margin guided 10-12% after a 7% Q1) −10 high regulatory/FTC risk = 73. Down from ~81: the old 30-45% CAGR no longer answers to the guided or 2030 series after the compounded-to-branded GLP-1 reset.
Price Scenarios (12–24 Months)
Valuation Multiples
| Price / Sales (FY26) | ~2.5× |
| EV / Adj EBITDA (FY26) | ~25× |
| Forward P/E (FY26) | N/M |
| Street 12-mo PT | ~$31 |
| FCF (Q1) | $53M |
Valuation has reset with the stock; the equity remains a high-volatility execution-and-regulatory position. Base case assumes the FY26 guide holds and FTC overhang is manageable — not a quality-compounder multiple.
Approximate figures as of August 10, 2026.
Where We Are vs Targets
Loading live price…
FTC suit escalates costs/CAC, branded weight-loss margins stay compressed, FY26 EBITDA misses — multiple compresses toward ~1.5× sales.
- FTC/state action forces material settlement, ad restrictions, or cancellation-UX changes that lift CAC
- Branded Wegovy/Ozempic mix keeps gross margin near mid-60s without H2 operating leverage
- Subscriber growth stalls below ~10% YoY as weight-loss ARPU normalises
FY26 revenue delivered near guide midpoint, Q2 confirms re-acceleration, Adj EBITDA margin exits toward guide, multiple holds ~2.5× sales.
- Q2–Q4 print inside the $2.8-3.0B / $275-350M bands (plus initial Eucalyptus contribution)
- Weight-loss settles into branded Novo mix with stabilising gross margin
- International (Eucalyptus + ZAVA/Livewell) and new categories reach a meaningful revenue share
Hims becomes the leading multi-country DTC chronic-care platform, 2030 path looks credible, Adj EBITDA margin expands toward mid-teens, multiple re-rates toward 4×+ sales.
- Subscriber base scales past 3.5M with improving NRR as diagnostics/personalisation land
- Eucalyptus integration lifts RoW without proportional margin dilution
- FTC resolved without franchise damage; category mix diversifies away from GLP-1 concentration